US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews
Executive Summary
FDA's Peter Stein calls idea "useful"; rare disease experts would temporarily serve on standing advisory committees when needed.
You may also be interested in...
Senate Budget Draft Would Be Less Generous To US FDA Than House For FY2023
Senate appropriations bill would take back some of increase House offered Center for Drug Evaluation and Research and other FDA programs, setting up negotiations as start of FY2023 nears.
Senate Budget Draft Would Be Less Generous To US FDA Than House For FY 2023
Senate appropriations bill would take back some of the increase the House offered the Center for Drug Evaluation and Research and other programs, setting up negotiations as next fiscal year nears.
Rare Disease Challenges At US FDA: CDER Director Says More Staff, Not Reorganization, Will Fix Issues
Rather than changing the agency's structure to create more focus on rare diseases, Patrizia Cavazzoni wants funding for people to do the necessary work.